Abstract

Aim

This study aims to evaluate the safety and efficacy of salvage HDR brachytherapy in patients who have undergone a thorough diagnostic process.

Materials and methods

100 prostate cancer patients – locally relapsed after previous radiotherapy – were treated with salvage HDR brachytherapy to a total dose of 24 Gy. Before treatment, the patients underwent PET imaging, prostate MRI, and prostate biopsies to confirm local relapse and exclude systemic disease. Concomitant ADT was applied in 69 patients. Toxicity and efficacy data were collected as a patient chart review. Toxicity was graded using Common Terminology Criteria for Adverse Events (CTCAE 5.0).

Results

The 3-year bDFS and OS were 74% (confidence interval [CI] 95%: 60–87%) and 93% (CI 95%: 84–100%), respectively. Acute Grade 1–2 genitourinary toxicity was observed in 70 patients, 58 patients with Grade 1 and 12 patients with Grade 2, respectively. Acute Grade 1 gastrointestinal toxicity was observed in 8 patients.

Conclusions

This retrospective study shows that salvage HDR brachytherapy is a well-tolerated and effective treatment for histologically proven, local radio-recurrent disease.

中文翻译：

---

前列腺癌的补救 HDR 近距离放射治疗：100 名连续患者的大量中心经验

摘要

目的

本研究旨在评估挽救性 HDR 近距离放射治疗对经过全面诊断过程的患者的安全性和有效性。

材料和方法

100 名前列腺癌患者——在之前的放疗后局部复发——接受了总剂量为 24 Gy 的挽救性 HDR 近距离放射治疗。治疗前，患者接受了 PET 成像、前列腺 MRI 和前列腺活检，以确认局部复发并排除全身性疾病。69 名患者同时应用了 ADT。收集毒性和疗效数据作为患者图表审查。使用不良事件通用术语标准 (CTCAE 5.0) 对毒性进行分级。

结果

3 年 bDFS 和 OS 分别为 74%（置信区间 [CI] 95%：60–87%）和 93%（CI 95%：84–100%）。在 70 名患者、58 名 1 级患者和 12 名 2 级患者中分别观察到急性 1-2 级泌尿生殖系统毒性。在 8 名患者中观察到急性 1 级胃肠道毒性。

结论

这项回顾性研究表明，挽救性 HDR 近距离放射治疗是一种耐受性良好且有效的治疗方法，可用于经组织学证实的局部放射复发性疾病。